{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T21:06:57Z","timestamp":1789160817956,"version":"build-2803163510"},"reference-count":77,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:00:00Z","timestamp":1786320000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004836","name":"Danmarks Frie Forskningsfond","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004836","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Brain, Behavior, & Immunity - Health"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.bbih.2026.101329","type":"journal-article","created":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T23:42:37Z","timestamp":1786405357000},"page":"101329","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Soluble urokinase plasminogen activator receptor \u2013 What are the clinical potentials in psychiatry?"],"prefix":"10.1016","volume":"56","author":[{"given":"Franziska Grundtvig","family":"Huber","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milo Wolfgang Pilgaard","family":"Kristensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mette \u00d8degaard","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torkel","family":"Vang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jimmi","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbih.2026.101329_bib1","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.769309","article-title":"Prevalence of overweight and obesity in people with severe mental illness: systematic review and meta-analysis","volume":"12","author":"Afzal","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.bbih.2026.101329_bib2","doi-asserted-by":"crossref","DOI":"10.1177\/11772719211034685","article-title":"suPAR cut-offs for risk stratification in patients with symptoms of COVID-19","volume":"16","author":"Altintas","year":"2021","journal-title":"Biomark. Insights"},{"issue":"663","key":"10.1016\/j.bbih.2026.101329_bib3","doi-asserted-by":"crossref","first-page":"436","DOI":"10.3399\/bjgp17X692621","article-title":"Physical health in severe mental illness","volume":"67","author":"Ashworth","year":"2017","journal-title":"Br. J. Gen. Pract."},{"issue":"9","key":"10.1016\/j.bbih.2026.101329_bib4","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1007\/s00134-012-2613-1","article-title":"Usefulness of suPAR as a biological marker in patients with systemic inflammation or infection: a systematic review","volume":"38","author":"Backes","year":"2012","journal-title":"Intensive Care Med."},{"issue":"11","key":"10.1016\/j.bbih.2026.101329_bib5","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/j.jclinepi.2005.03.011","article-title":"Psychiatric and somatic comorbidities are negatively associated with quality of life in physically ill patients","volume":"58","author":"Baumeister","year":"2005","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.bbih.2026.101329_bib6","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2023.1175171","article-title":"Alterations in inflammatory markers after a 12-week exercise program in individuals with schizophrenia-a randomized controlled trial","volume":"14","author":"Bigseth","year":"2023","journal-title":"Front. Psychiatr."},{"issue":"1","key":"10.1016\/j.bbih.2026.101329_bib7","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1186\/s12888-021-03522-6","article-title":"Exploring low grade inflammation by soluble urokinase plasminogen activator receptor levels in schizophrenia: a sex-dependent association with depressive symptoms","volume":"21","author":"Bigseth","year":"2021","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.bbih.2026.101329_bib8","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.schres.2020.11.051","article-title":"Elevated levels of soluble urokinase plasminogen activator receptor as a low-grade inflammation marker in schizophrenia: a case-control study","volume":"228","author":"Bigseth","year":"2021","journal-title":"Schizophr. Res."},{"issue":"7","key":"10.1016\/j.bbih.2026.101329_bib9","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/eci.12278","article-title":"Associations of suPAR with lifestyle and cardiometabolic risk factors","volume":"44","author":"Botha","year":"2014","journal-title":"Eur. J. Clin. Invest."},{"key":"10.1016\/j.bbih.2026.101329_bib10","article-title":"PTSD and suPAR: a multicohort investigation of chronic inflammation","volume":"131","author":"Bourassa","year":"2025","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.bbih.2026.101329_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbi.2025.106159","article-title":"PTSD and suPAR: a multicohort investigation of chronic inflammation","volume":"131","author":"Bourassa","year":"2026","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.bbih.2026.101329_bib12","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.bbi.2021.06.018","article-title":"Linking stressful life events and chronic inflammation using suPAR (soluble urokinase plasminogen activator receptor)","volume":"97","author":"Bourassa","year":"2021","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.bbih.2026.101329_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.psyneuen.2023.106077","article-title":"Longitudinal links between early adolescent temperament and inflammation among young black adults","volume":"152","author":"Brody","year":"2023","journal-title":"Psychoneuroendocrinology"},{"issue":"1","key":"10.1016\/j.bbih.2026.101329_bib14","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/s41398-022-02142-2","article-title":"Transdiagnostic inflammatory subgroups among psychiatric disorders and their relevance to role functioning: a nested case-control study of the ALSPAC cohort","volume":"12","author":"Byrne","year":"2022","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.bbih.2026.101329_bib15","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.neubiorev.2017.03.003","article-title":"Acute variations of cytokine levels after antipsychotic treatment in drug-naive subjects with a first-episode psychosis: a meta-analysis","volume":"77","author":"Capuzzi","year":"2017","journal-title":"Neurosci. Biobehav. Rev."},{"issue":"5","key":"10.1016\/j.bbih.2026.101329_bib16","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/ana.20076","article-title":"The urokinase receptor is overexpressed in the AIDS dementia complex and other neurological manifestations","volume":"55","author":"Cinque","year":"2004","journal-title":"Ann. Neurol."},{"issue":"8","key":"10.1016\/j.bbih.2026.101329_bib17","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1016\/j.drudis.2020.06.013","article-title":"COVID-19 and pneumonia: a role for the uPA\/uPAR system","volume":"25","author":"D'Alonzo","year":"2020","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.bbih.2026.101329_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.psyneuen.2025.107405","article-title":"Inflammatory biomarkers and childhood maltreatment: a cluster analysis in patients with eating disorders","volume":"174","author":"Dani","year":"2025","journal-title":"Psychoneuroendocrinology"},{"issue":"1","key":"10.1016\/j.bbih.2026.101329_bib19","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.jcrc.2013.08.005","article-title":"Soluble urokinase-type plasminogen activator receptor as a prognostic biomarker in critically ill patients","volume":"29","author":"Donadello","year":"2014","journal-title":"J. Crit. Care"},{"key":"10.1016\/j.bbih.2026.101329_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.schres.2020.12.020","article-title":"Peripheral immune markers and antipsychotic non-response in psychosis","volume":"230","author":"Enache","year":"2021","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.bbih.2026.101329_bib21","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.cca.2015.02.031","article-title":"Soluble urokinase plasminogen activator receptor--a valuable biomarker in systemic lupus erythematosus?","volume":"444","author":"Enocsson","year":"2015","journal-title":"Clin. Chim. Acta"},{"issue":"Suppl. 1","key":"10.1016\/j.bbih.2026.101329_bib22","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1016\/j.ijantimicag.2015.10.011","article-title":"suPAR: the unspecific marker for disease presence, severity and prognosis","volume":"46","author":"Eugen-Olsen","year":"2015","journal-title":"Int. J. Antimicrob. Agents"},{"issue":"4","key":"10.1016\/j.bbih.2026.101329_bib23","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/eci.12593","article-title":"Plasma suPAR is lowered by smoking cessation: a randomized controlled study","volume":"46","author":"Eugen-Olsen","year":"2016","journal-title":"Eur. J. Clin. Invest."},{"key":"10.1016\/j.bbih.2026.101329_bib24","article-title":"Natural-cause mortality and C-reactive protein levels in patients with schizophrenia spectrum disorders: a prospective total cohort study","volume":"50","author":"Fathian","year":"2025","journal-title":"Brain Behav Immun Health"},{"key":"10.1016\/j.bbih.2026.101329_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopsycho.2021.108147","article-title":"The levels of soluble urokinase plasminogen activator receptor (suPAR) in saliva are influenced by acute stress","volume":"165","author":"Fernandez-Botran","year":"2021","journal-title":"Biol. Psychol."},{"issue":"8","key":"10.1016\/j.bbih.2026.101329_bib26","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S2215-0366(19)30132-4","article-title":"The Lancet psychiatry commission: a blueprint for protecting physical health in people with mental illness","volume":"6","author":"Firth","year":"2019","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.bbih.2026.101329_bib27","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.psychres.2016.01.018","article-title":"Serum soluble urokinase-type plasminogen activator receptor levels in male patients with acute exacerbation of schizophrenia","volume":"236","author":"Genc","year":"2016","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.bbih.2026.101329_bib28","doi-asserted-by":"crossref","DOI":"10.1177\/1177271917704193","article-title":"Effects of acute exercise on circulating soluble form of the urokinase receptor in patients with major depressive disorder","volume":"12","author":"Gustafsson","year":"2017","journal-title":"Biomark. Insights"},{"issue":"10","key":"10.1016\/j.bbih.2026.101329_bib29","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0110555","article-title":"Soluble urokinase plasminogen activator receptor as a marker for use of antidepressants","volume":"9","author":"Haastrup","year":"2014","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.bbih.2026.101329_bib30","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/S2215-0366(23)00025-1","article-title":"Alteration patterns of peripheral concentrations of cytokines and associated inflammatory proteins in acute and chronic stages of schizophrenia: a systematic review and network meta-analysis","volume":"10","author":"Halstead","year":"2023","journal-title":"Lancet Psychiatry"},{"issue":"4","key":"10.1016\/j.bbih.2026.101329_bib31","doi-asserted-by":"crossref","first-page":"59","DOI":"10.5527\/wjn.v10.i4.59","article-title":"Prediction of mortality among patients with chronic kidney disease: a systematic review","volume":"10","author":"Hansrivijit","year":"2021","journal-title":"World J. Nephrol."},{"key":"10.1016\/j.bbih.2026.101329_bib32","article-title":"SuPAR in major depression: association with 26 weeks antidepressant response and 10-year depression outcomes","volume":"33","author":"Haupt","year":"2023","journal-title":"Brain Behav Immun Health"},{"key":"10.1016\/j.bbih.2026.101329_bib33","doi-asserted-by":"crossref","first-page":"91","DOI":"10.4137\/BMI.S19876","article-title":"Risk factors associated with serum levels of the inflammatory biomarker soluble urokinase plasminogen activator receptor in a general population","volume":"9","author":"Haupt","year":"2014","journal-title":"Biomark. Insights"},{"key":"10.1016\/j.bbih.2026.101329_bib34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12979-018-0141-8","article-title":"Healthy lifestyles reduce suPAR and mortality in a Danish general population study","volume":"16","author":"Haupt","year":"2019","journal-title":"Immun. Ageing"},{"issue":"10","key":"10.1016\/j.bbih.2026.101329_bib35","first-page":"1293","article-title":"suPAR: a new biomarker for cardiovascular disease?","volume":"31","author":"Hodges","year":"2015","journal-title":"Can. J. Cardiol."},{"issue":"1","key":"10.1016\/j.bbih.2026.101329_bib36","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/j.1365-2796.2011.02363.x","article-title":"Plasma level of soluble urokinase-type plasminogen activator receptor as a predictor of disease severity and case fatality in patients with bacteraemia: a prospective cohort study","volume":"270","author":"Huttunen","year":"2011","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.bbih.2026.101329_bib37","doi-asserted-by":"crossref","DOI":"10.14744\/etd.2018.18188","article-title":"Evaluation of supar levels in attention deficit and hyperactivity disorder etiopathogenesis","author":"Irmak","year":"2019","journal-title":"Erciyes Medical Journal"},{"issue":"4","key":"10.1016\/j.bbih.2026.101329_bib38","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.scib.2024.09.041","article-title":"Plasma proteomics identifies proteins and pathways associated with incident depression in 46,165 adults","volume":"70","author":"Kang","year":"2025","journal-title":"Sci Bull (Beijing)."},{"issue":"1","key":"10.1016\/j.bbih.2026.101329_bib39","doi-asserted-by":"crossref","DOI":"10.1192\/j.eurpsy.2022.2341","article-title":"Mortality in people with mental disorders in Poland: a nationwide, register-based cohort study","volume":"66","author":"Kiejna","year":"2023","journal-title":"Eur. Psychiatry"},{"issue":"3","key":"10.1016\/j.bbih.2026.101329_bib40","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s40618-020-01358-7","article-title":"Plasma levels of soluble urokinase plasminogen activator receptor (suPAR) and high-sensitivity C-reactive protein after Roux-en-Y gastric bypass or sleeve gastrectomy: a 1-year prospective observational study","volume":"44","author":"Kokkinos","year":"2021","journal-title":"J. Endocrinol. Investig."},{"key":"10.1016\/j.bbih.2026.101329_bib41","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.bbi.2021.12.027","article-title":"Longitudinal associations between adolescents' individualised risk for depression and inflammation in a UK cohort study","volume":"101","author":"Latham","year":"2022","journal-title":"Brain Behav. Immun."},{"issue":"2","key":"10.1016\/j.bbih.2026.101329_bib42","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0281667","article-title":"Use of urgent, emergency and acute care by mental health service users: a record-level cohort study","volume":"18","author":"Lewis","year":"2023","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.bbih.2026.101329_bib43","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.ijcard.2012.03.040","article-title":"CRP and suPAR are differently related to anthropometry and subclinical organ damage","volume":"167","author":"Lyngbaek","year":"2013","journal-title":"Int. J. Cardiol."},{"issue":"1","key":"10.1016\/j.bbih.2026.101329_bib44","first-page":"104","article-title":"SERUM uPAR CONCENTRATION IN PATIENTS WITH A DEPRESSIVE DISORDERS - a preliminary study","volume":"34","author":"Malujlo-Balcerska","year":"2022","journal-title":"Psychiatr. Danub."},{"issue":"1","key":"10.1016\/j.bbih.2026.101329_bib45","doi-asserted-by":"crossref","first-page":"348","DOI":"10.5114\/aoms\/178276","article-title":"Systemic concentrations of IL-18, TFG-beta, RANTES, ICAM-1 and uPAR as combined pathway-related factors may help in identification of patients suffering from depressive disorder","volume":"20","author":"Malujlo-Balcerska","year":"2024","journal-title":"Arch. Med. Sci."},{"issue":"6","key":"10.1016\/j.bbih.2026.101329_bib46","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1007\/s43440-023-00548-3","article-title":"Serum levels of biomarkers that may link chronic obstructive pulmonary disease and depressive disorder","volume":"75","author":"Malujlo-Balcerska","year":"2023","journal-title":"Pharmacol. Rep."},{"issue":"7","key":"10.1016\/j.bbih.2026.101329_bib47","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.biopsych.2011.04.013","article-title":"Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects","volume":"70","author":"Miller","year":"2011","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.bbih.2026.101329_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.psyneuen.2021.105200","article-title":"Immune-inflammatory markers and psychosis risk: a systematic review and meta-analysis","volume":"127","author":"Misiak","year":"2021","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.bbih.2026.101329_bib49","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.bbi.2023.03.025","article-title":"Associations between plasma inflammatory markers and psychotic disorder, depressive disorder and generalised anxiety disorder in early adulthood: a nested case-control study","volume":"111","author":"Mongan","year":"2023","journal-title":"Brain Behav. Immun."},{"issue":"5","key":"10.1016\/j.bbih.2026.101329_bib50","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1093\/schbul\/sby024","article-title":"Inflammation in schizophrenia: pathogenetic aspects and therapeutic considerations","volume":"44","author":"Muller","year":"2018","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.bbih.2026.101329_bib51","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.bbi.2024.06.003","article-title":"Associations between soluble urokinase plasminogen activator receptor (suPAR) concentration and psychiatric disorders \u2013 a systematic review and meta-analysis","volume":"120","author":"Murphy","year":"2024","journal-title":"Brain Behav. Immun."},{"issue":"4","key":"10.1016\/j.bbih.2026.101329_bib52","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1093\/schbul\/sbad017","article-title":"Socioenvironmental adversity and adolescent psychotic experiences: exploring potential mechanisms in a UK longitudinal cohort","volume":"49","author":"Newbury","year":"2023","journal-title":"Schizophr. Bull."},{"issue":"3","key":"10.1016\/j.bbih.2026.101329_bib53","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1093\/schbul\/sbu118","article-title":"Soluble urokinase-type plasminogen activator receptor levels in patients with schizophrenia","volume":"41","author":"Nielsen","year":"2015","journal-title":"Schizophr. Bull."},{"issue":"1","key":"10.1016\/j.bbih.2026.101329_bib54","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0055176","article-title":"Excess mortality, causes of death and life expectancy in 270,770 patients with recent onset of mental disorders in Denmark, Finland and Sweden","volume":"8","author":"Nordentoft","year":"2013","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.bbih.2026.101329_bib55","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1080\/00365540310017366","article-title":"Soluble urokinase receptor is elevated in cerebrospinal fluid from patients with purulent meningitis and is associated with fatal outcome","volume":"36","author":"Ostergaard","year":"2004","journal-title":"Scand. J. Infect. Dis."},{"key":"10.1016\/j.bbih.2026.101329_bib56","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.psyneuen.2018.02.009","article-title":"Decreased circulating urokinase plasminogen activator receptor (uPAR) concentration in acute episodes of bipolar disorder; could it be a reflection of axonal injury?","volume":"90","author":"Ozpercin","year":"2018","journal-title":"Psychoneuroendocrinology"},{"issue":"16","key":"10.1016\/j.bbih.2026.101329_bib57","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S0033291724002848","article-title":"Cannabis use in youth is associated with chronic inflammation","volume":"54","author":"Power","year":"2024","journal-title":"Psychol. Med."},{"issue":"2","key":"10.1016\/j.bbih.2026.101329_bib58","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s00787-023-02181-0","article-title":"Inflammatory burden of adolescents with childhood maltreatment: results from baseline data of a school cohort","volume":"33","author":"Qu","year":"2024","journal-title":"Eur. Child Adolesc. Psychiatr."},{"issue":"11","key":"10.1016\/j.bbih.2026.101329_bib59","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1136\/emermed-2015-205444","article-title":"Soluble urokinase plasminogen activator receptor (suPAR) in acute care: a strong marker of disease presence and severity, readmission and mortality. A retrospective cohort study","volume":"33","author":"Rasmussen","year":"2016","journal-title":"Emerg. Med. J."},{"issue":"2","key":"10.1016\/j.bbih.2026.101329_bib60","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/jcpp.12928","article-title":"Cumulative childhood risk is associated with a new measure of chronic inflammation in adulthood","volume":"60","author":"Rasmussen","year":"2019","journal-title":"J Child Psychol Psychiatry"},{"key":"10.1016\/j.bbih.2026.101329_bib61","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.780641","article-title":"Soluble urokinase plasminogen activator receptor (suPAR) as a biomarker of systemic chronic inflammation","volume":"12","author":"Rasmussen","year":"2021","journal-title":"Front. Immunol."},{"issue":"45","key":"10.1016\/j.bbih.2026.101329_bib62","article-title":"Role of soluble urokinase type plasminogen activator receptor (suPAR) in predicting mortality, readmission, length of stay and discharge in emergency patients: a systematic review and meta analysis","volume":"102","author":"Rehan","year":"2023","journal-title":"Medicine (Baltim.)"},{"key":"10.1016\/j.bbih.2026.101329_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.neubiorev.2023.105425","article-title":"Major depressive disorder as a neuro-immune disorder: origin, mechanisms, and therapeutic opportunities","volume":"155","author":"Reus","year":"2023","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.bbih.2026.101329_bib64","doi-asserted-by":"crossref","first-page":"35","DOI":"10.4137\/BMI.S11270","article-title":"Decreased epidermal growth factor (EGF) associated with HMGB1 and increased hyperactivity in children with autism","volume":"8","author":"Russo","year":"2013","journal-title":"Biomark Insights"},{"issue":"9","key":"10.1016\/j.bbih.2026.101329_bib65","first-page":"85","article-title":"Decreased mitogen inducible gene 6 (MIG-6) associated with symptom severity in children with autism","volume":"2014","author":"Russo","year":"2014","journal-title":"Biomark. Insights"},{"key":"10.1016\/j.bbih.2026.101329_bib66","first-page":"107","article-title":"Decreased hepatocyte growth factor (HGF) and gamma aminobutyric acid (GABA) in individuals with obsessive-compulsive disorder (OCD)","volume":"8","author":"Russo","year":"2013","journal-title":"Biomark. Insights"},{"issue":"4","key":"10.1016\/j.bbih.2026.101329_bib67","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1080\/00365513.2020.1741674","article-title":"Validation of suPAR turbidimetric assay on cobas\u00ae (c502 and c702) and comparison to suPAR ELISA","volume":"80","author":"Skovsted","year":"2020","journal-title":"Scand. J. Clin. Lab. Investig."},{"issue":"3","key":"10.1016\/j.bbih.2026.101329_bib68","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.jemermed.2021.03.012","article-title":"Soluble urokinase plasminogen activator receptor as a decision marker for early discharge of patients with COVID-19 symptoms in the emergency department","volume":"61","author":"Stauning","year":"2021","journal-title":"J. Emerg. Med."},{"key":"10.1016\/j.bbih.2026.101329_bib69","doi-asserted-by":"crossref","DOI":"10.1016\/j.metop.2025.100347","article-title":"Unveiling the link between chronic inflammation and cancer","volume":"25","author":"Tripathi","year":"2025","journal-title":"Metabol Open"},{"key":"10.1016\/j.bbih.2026.101329_bib70","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.bbi.2021.08.209","article-title":"Associations between childhood victimization, inflammatory biomarkers and psychotic phenomena in adolescence: a longitudinal cohort study","volume":"98","author":"Trotta","year":"2021","journal-title":"Brain Behav. Immun."},{"issue":"12","key":"10.1016\/j.bbih.2026.101329_bib71","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1111\/jgh.12639","article-title":"Serum soluble urokinase plasminogen activator receptor in alcoholics: relation to liver disease severity, fibrogenesis, and alcohol use","volume":"29","author":"Tuomi","year":"2014","journal-title":"J. Gastroenterol. Hepatol."},{"issue":"3","key":"10.1016\/j.bbih.2026.101329_bib72","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1017\/S2045796012000571","article-title":"Emergency department staff views and experiences on diagnostic overshadowing related to people with mental illness","volume":"22","author":"van Nieuwenhuizen","year":"2013","journal-title":"Epidemiol. Psychiatr. Sci."},{"issue":"1","key":"10.1016\/j.bbih.2026.101329_bib73","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s40620-022-01344-7","article-title":"Assay-related differences in SuPAR levels: implications for measurement and data interpretation","volume":"36","author":"Vasbinder","year":"2023","journal-title":"J. Nephrol."},{"issue":"3","key":"10.1016\/j.bbih.2026.101329_bib74","doi-asserted-by":"crossref","first-page":"133","DOI":"10.14740\/jocmr4459","article-title":"Soluble urokinase plasminogen activator receptor as a diagnostic and prognostic biomarker in cardiac disease","volume":"13","author":"Velissaris","year":"2021","journal-title":"J. Clin. Med. Res."},{"issue":"10","key":"10.1016\/j.bbih.2026.101329_bib75","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0140052","article-title":"Increased soluble urokinase-type plasminogen activator receptor (suPAR) levels in plasma of suicide attempters","volume":"10","author":"Ventorp","year":"2015","journal-title":"PLoS One"},{"issue":"18","key":"10.1016\/j.bbih.2026.101329_bib76","article-title":"The association of suPAR with cardiovascular risk factors in young and healthy adults","volume":"13","author":"Wohlwend","year":"2023","journal-title":"Diagnostics (Basel)"},{"issue":"Pt B","key":"10.1016\/j.bbih.2026.101329_bib77","article-title":"suPAR as a mediator between childhood trauma and adolescent depression","volume":"393","author":"Xie","year":"2026","journal-title":"J. Affect. Disord."}],"container-title":["Brain, Behavior, & Immunity - Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666354626001626?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666354626001626?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T20:18:01Z","timestamp":1789157881000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666354626001626"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":77,"alternative-id":["S2666354626001626"],"URL":"https:\/\/doi.org\/10.1016\/j.bbih.2026.101329","relation":{},"ISSN":["2666-3546"],"issn-type":[{"value":"2666-3546","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Soluble urokinase plasminogen activator receptor \u2013 What are the clinical potentials in psychiatry?","name":"articletitle","label":"Article Title"},{"value":"Brain, Behavior, & Immunity - Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbih.2026.101329","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101329"}}